Literature DB >> 24816242

Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia.

Daria G Valerio1, Jenny E Katsman-Kuipers1, Joop H Jansen2, Lonneke J Verboon1, Valerie de Haas3, Jan Stary4, André Baruchel5, Martin Zimmermann6, Rob Pieters1, Dirk Reinhardt6, Marry M van den Heuvel-Eibrink1, C Michel Zwaan7.   

Abstract

Entities:  

Keywords:  DNMT3A; IDH; TET2; pediatric acute myeloid leukemia

Mesh：

Year:  2014        PMID： 24816242      PMCID： PMC4116843          DOI： 10.3324/haematol.2013.094565

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.

Authors:  H Makishima; A M Jankowska; R V Tiu; H Szpurka; Y Sugimoto; Z Hu; Y Saunthararajah; K Guinta; M A Keddache; P Putnam; M A Sekeres; A R Moliterno; A F List; M A McDevitt; J P Maciejewski
Journal:  Leukemia       Date:  2010-08-19       Impact factor: 11.528

2.  TET2 mutations in childhood leukemia.

Authors:  S M C Langemeijer; J H Jansen; J Hooijer; P van Hoogen; E Stevens-Linders; M Massop; E Waanders; S V van Reijmersdal; M J P L Stevens-Kroef; C M Zwaan; M M van den Heuvel-Eibrink; E Sonneveld; P M Hoogerbrugge; A Geurts van Kessel; R P Kuiper
Journal:  Leukemia       Date:  2010-11-02       Impact factor: 11.528

3.  Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model.

Authors:  I H I M Hollink; Q Feng; A A Danen-van Oorschot; S T C J M Arentsen-Peters; L J Verboon; P Zhang; V de Haas; D Reinhardt; U Creutzig; J Trka; R Pieters; M M van den Heuvel-Eibrink; J Wang; C M Zwaan
Journal:  Leukemia       Date:  2011-08-12       Impact factor: 11.528

4.  TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Klaus H Metzeler; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Heiko Becker; John Curfman; Kelsi B Holland; Sebastian Schwind; Susan P Whitman; Yue-Zhong Wu; William Blum; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

5.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Authors:  Klaus H Metzeler; Heiko Becker; Kati Maharry; Michael D Radmacher; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

6.  DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Authors:  K H Metzeler; A Walker; S Geyer; R Garzon; R B Klisovic; C D Bloomfield; W Blum; G Marcucci
Journal:  Leukemia       Date:  2011-11-29       Impact factor: 11.528

7.  Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.

Authors:  Brian V Balgobind; Iris H I M Hollink; Susan T C J M Arentsen-Peters; Martin Zimmermann; Jochen Harbott; H Berna Beverloo; Anne R M von Bergh; Jacqueline Cloos; Gertjan J L Kaspers; Valerie de Haas; Zuzana Zemanova; Jan Stary; Jean-Michel Cayuela; Andre Baruchel; Ursula Creutzig; Dirk Reinhardt; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

Review 8.  Acute leukemia: a pediatric perspective.

Authors:  James R Downing; Kevin M Shannon
Journal:  Cancer Cell       Date:  2002-12       Impact factor: 31.743

9.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

10.  Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.

Authors:  F Damm; F Thol; I Hollink; M Zimmermann; K Reinhardt; M M van den Heuvel-Eibrink; C M Zwaan; V de Haas; U Creutzig; J-H Klusmann; J Krauter; M Heuser; A Ganser; D Reinhardt; C Thiede
Journal:  Leukemia       Date:  2011-06-07       Impact factor: 12.883
View more
  4 in total

Review 1.  Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention.

Authors:  Thomas Mercher; Juerg Schwaller
Journal:  Front Pediatr       Date:  2019-10-15       Impact factor: 3.418

Review 2.  Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia.

Authors:  Huan Xu; Yuxi Wen; Runming Jin; Hongbo Chen
Journal:  Front Pediatr       Date:  2022-09-06       Impact factor: 3.569

Review 3.  Pediatric AML: From Biology to Clinical Management.

Authors:  Jasmijn D E de Rooij; C Michel Zwaan; Marry van den Heuvel-Eibrink
Journal:  J Clin Med       Date:  2015-01-09       Impact factor: 4.241

Review 4.  Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2020-08-26       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.